|  |  |  |  |
| --- | --- | --- | --- |
|  | Complete Record |  |  |
|  | NO | Yes | P-value |  |
| Case,n | 7 | 147 |  |  |
| Mean age (SD), y | 56.6 ± 9.3 | 55.7 ± 12.4 | 0.855 |  |
| Mean BMI (SD), kg/m2 | 20.9 ± 1.1 | 22.2 ± 4.1 | 0.419 |  |
| Sex,% |  |  | 0.479 |  |
| female | 4 (57.1%) | 64 (43.5%) |  |  |
| male | 3 (42.9%) | 83 (56.5%) |  |  |
| WHO performance status,% |  |  | 0.09 |  |
|  0-1 | 1 (14.3%) | 69 (46.9%) |  |  |
|  2-4 | 6 (85.7%) | 78 (53.1%) |  |  |
| Differentiation,% |  |  | 0.437 |  |
|  no/low | 2 (28.6%) | 28 (19.0%) |  |  |
| middle/high | 3 (42.9%) | 97 (66.0%) |  |  |
|  Not Record | 2 (28.6%) | 22 (15.0%) |  |  |
| Primary Site,% |  |  | 0.937 |  |
|  Right | 2 (28.6%) | 40 (27.2%) |  |  |
|  Left | 5 (71.4%) | 107 (72.8%) |  |  |
| Surgery of primary sites,% |  |  | 0.878 |  |
|  None | 2 (28.6%) | 39 (26.5%) |  |  |
|  Palliative | 1 (14.3%) | 33 (22.4%) |  |  |
| Radical | 4 (57.1%) | 75 (51.0%) |  |  |
| No. of metastatic sites,% |  |  | 0.159 |  |
| 1 | 5 (71.4%) | 59 (40.1%) |  |  |
| 2 | 2 (28.6%) | 44 (29.9%) |  |  |
| ≥3 | 0 ( 0.0%) | 44 (29.9%) |  |  |
| Line of treatment,% |  |  | 0.067 |  |
| 1st | 0 ( 0.0%) | 24 ( 16.3%) |  |  |
|  2nd |  7 (100.0%) | 71 ( 48.3%) |  |  |
| 1st+2nd | 0 ( 0.0%) | 21 ( 14.3%) |  |  |
| 3rd-5th |  |  |  |  |
| Chemotherapy used,% |  |  |  0.342 |  |
| capeOX/FOLFOX |  3 (42.9%) | 75 (51.0%) |  |  |
| FOLFIRI | 3 (42.9%) | 30 (20.4%) |  |  |
| others | 1 (14.3%) | 42 (28.6%) |  |  |